Distinguished Abstract Award to be presented Wednesday July 31 at ADLM Annual Meeting

Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA-Dx™) for early detection of solid tumor cancers, will present its latest clinical evidence as a Distinguished Abstract at the Academy of Diagnostics & Laboratory Medicine Annual Meeting in Chicago July 28 – August 1, 2024.

Dxcover’s abstract entitled “Multi-omic blood test for early detection of cancer and pre-cancer” is one of only 29 submissions the Academy of Diagnostics & Laboratory Medicine Fellows selected for scientific excellence from a pool of more than 775 abstracts accepted for ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo). Winning abstracts will display the Academy blue ribbon during the ADLM 2024 poster sessions.

President and Chief Executive Officer Professor Matthew J. Baker PhD will present the abstract July 31 9:30am – 5:00pm CT in the Poster Hall. “We are honored that our work has been recognized with a Distinguished Abstract Award by the Academy. We will showcase how our novel approach enables highly accurate early cancer and pre-cancer detection to improve patient outcomes. The Dxcover approach provides a low barrier for integration of our multi-omic blood test into existing pathways as the technology is rapid, simple to use, cost-effective and has minimal sample preparation."

The company is establishing its US operations while collaborating with US clinicians and healthcare sites to demonstrate the Dxcover® PANAROMIC™ platform for early detection capabilities in solid tumor cancers, including advanced adenoma/colorectal, brain, lung, breast, pancreatic, kidney, liver and others. The turn-key workflow of the Drop.Dry.Detect.® platform enables rapid turnaround of accurate cancer detection results within same day of specimen receipt.

About Dxcover Limited

The Dxcover PANAROMIC platform utilizes multi-omic spectral analysis to detect cancer. This technology goes beyond traditional liquid biopsy methods by analyzing signals missed by current cell-free DNA testing. Dxcover's PANAROMIC platform has achieved impressive results, including 99% specificity for early-stage tumors and validation in over 3,000 patient samples across various cancers. This versatile platform can be adapted for high sensitivity (ruling out cancer) or high specificity (ruling in cancer), making it a valuable tool for clinicians, pharmaceutical and biotechnology cancer researchers and oncology diagnostic platforms. Additionally, Dxcover's platform is patented in the US, EU, and China. The company was recently incorporated in the US and is establishing US operations in Nashville TN.

For further information https://www.dxcover.com/science

Stacy Chick stacy.chick@dxcover.com